Key terms
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GRI news
Apr 16
8:41am ET
GRI Bio issued grant from Korean Intellectual Property Office
Apr 01
7:40am ET
GRI Bio sees cash runway into 3Q24
Apr 01
7:39am ET
GRI Bio reports 2023 EPS ($28.25) vs. ($24.95) last year
Mar 04
8:39am ET
GRI Bio receives MRHA authorization to conduct Phase 2a study of GRI-0621
Feb 02
8:03am ET
GRI Bio prices 5M shares at $1.10 in public offering
Jan 29
7:50pm ET
GRI Bio Inc trading halted, news pending
Jan 26
8:07am ET
GRI Bio announces 1-for-7 reverse stock split
GRI Financials
Key terms
Ad Feedback
GRI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GRI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
